*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below. |
| Put Medicus Pharma on Your Radar |
| | | Hey Folks, Every year, millions of Americans receive a cancer diagnosis that doesn't threaten their life — but the treatment leaves a lasting mark.
That's the reality for patients with basal cell carcinoma, the most common form of cancer in the United States. The standard of care works, but it involves surgery.
Medicus Pharma Ltd. (MDCX) is developing what could be the first non-surgical treatment for this condition — a dissolvable microneedle patch that delivers chemotherapy directly to the tumor. The company's lead asset has already shown over 60% complete clinical clearance in interim data, with topline results expected in the first half of 2026. | | | The Problem With the Most Common Cancer in America
Basal cell carcinoma, or BCC, is not just the most common skin cancer — it's the single most common form of cancer in the entire United States, with an estimated 3.6 million cases diagnosed every year. Nearly one in five Americans will develop it over a lifetime, and the incidence rate has been increasing at over 10% annually in white populations.
The good news: it's rarely fatal. The bad news: the standard treatment is Mohs surgery, a procedure where doctors cut the cancer out of the skin layer by layer under a microscope.
The challenges with the current standard of care are significant:
- Cure rates are above 95%, but the procedure is invasive and leaves visible scarring
- When tumors appear on the face, nose, or eyelids, cosmetic disfigurement becomes a serious concern
- Elderly patients who cannot tolerate surgery have limited alternatives
- Patients with Gorlin Syndrome, who develop hundreds of tumors over their lifetime, face a near-impossible surgical burden
- The estimated market opportunity for BCC treatment is approximately $2 billion
For a cancer that rarely kills, the current treatment carries consequences that many patients and physicians would prefer to avoid. That gap represents a meaningful unmet need.
Enter SkinJect: A Band-Aid That Kills Cancer
Medicus Pharma developed a product called SkinJect built around a straightforward concept. It's a patented dissolvable microneedle patch loaded with doxorubicin, a well-established chemotherapy agent. The patch is placed directly on the tumor, the microneedles dissolve into the skin, and the drug is delivered straight to the cancer cells — no surgery, no systemic exposure, no operating room required.
The clinical data gathered so far includes:
- Phase 1 completed in March 2021, meeting its primary endpoint of safety and tolerability
- No dose-limiting toxicities and no serious adverse events across all 13 Phase 1 patients
- Six out of 13 Phase 1 participants achieved complete responses, meaning cancer was histologically absent upon tissue examination
- Phase 2 (the SkinJect 003 study) is a randomized, double-blind, placebo-controlled trial across nine U.S. clinical sites
- Enrollment of 90 patients was completed in December 2025
- Interim analysis after more than 50% of targeted patients were randomized showed greater than 60% complete clinical clearance
Topline results from the Phase 2 study are expected in the first half of 2026, which could represent a near-term catalyst for the company. | | | Regulatory and Partnership Progress
Beyond the clinical data, Medicus has been building out its regulatory and commercial infrastructure.
Several developments are worth noting:
- The FDA has supported the 505(b)(2) regulatory pathway for SkinJect, which could accelerate development timelines and reduce costs compared to a traditional new drug application
- An end-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to establish the Phase 3 pathway
- The company has a strategic collaboration with the Gorlin Syndrome Alliance to pursue an expanded access program, giving patients with this rare genetic condition supervised access to SkinJect
- An application has been submitted under the FDA Commissioner's National Priority Voucher Program, which could fast-track the review timeline
- Clinical trials are being expanded internationally, with studies underway in the UK and UAE
A Second Pipeline Asset: Teverlex and Prostate Cancer
SkinJect is not Medicus Pharma's only development program. In September 2025, the company completed the acquisition of Antev Limited, a UK-based clinical-stage biotech developing Teverlex — a next-generation GnRH antagonist targeting advanced prostate cancer.
The rationale behind Teverlex centers on a significant gap in the existing treatment landscape:
- Approximately 300,000 to 500,000 men in the U.S. are living with advanced prostate cancer
- The standard treatment is androgen deprivation therapy (ADT), which lowers testosterone to slow disease progression
- Existing GnRH agonists — a common class of ADT drugs — significantly increase cardiovascular risk
- Cardiovascular disease accounts for roughly 30% of all non-cancer deaths in prostate cancer patients
- Teverlex is designed to suppress testosterone rapidly without the initial testosterone surge that agonists cause, with a potentially more favorable cardiovascular safety profile
The FDA has granted clearance for a Phase 2B study on Teverlex, adding a second clinical catalyst to the company's near-term pipeline. | | | Key Catalysts to Watch
For those conducting due diligence on Medicus Pharma, several developments could shape the company's trajectory in the coming months:
✔️ Topline Phase 2 results for SkinJect expected in the first half of 2026 ✔️ End-of-Phase 2 FDA meeting to establish the Phase 3 design for SkinJect ✔️ Progression of the Phase 2B Teverlex study following FDA clearance ✔️ Potential outcomes from the FDA National Priority Voucher Program application ✔️ International expansion of clinical trials in the UK and UAE |  | Worth Monitoring?
Medicus Pharma is developing what could be the first non-surgical treatment for the single most common cancer in the United States. The early data has shown promising signals, a major regulatory readout is approaching, and a second pipeline asset adds another dimension to the story.
For those with an interest in clinical-stage oncology companies, MDCX may be worth keeping an eye on.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to indra21poetra@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of Medicus Pharma Ltd. (MDCX) from March 2, 2026 to March 5, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Medicus Pharma Ltd. (MDCX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Medicus Pharma Ltd. (MDCX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Medicus Pharma Ltd. (MDCX), increased trading volume, and possibly an increased share price of Medicus Pharma Ltd. (MDCX), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
Tidak ada komentar:
Posting Komentar